TRAWS PHARMA INC (TRAW) Stock News

USA - NASDAQ:TRAW - US68232V8845 - Common Stock

2.11 USD

-0.02 (-0.94%)

Last: 11/19/2025, 2:53:49 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TRAW Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Chartmill - Mentions: CDTX AVXL SRRK KXIN ...

News Image

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session.

6 days ago - By: Chartmill - Mentions: CDTX AVXL BCAB NVVE ...

News Image

Which stocks are moving on Friday?

6 days ago - By: Benzinga - Mentions: PTN ZYXI AVXL CDTX ...

12 Health Care Stocks Moving In Friday's Intraday Session

7 days ago - By: Traws Pharma, Inc.

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

7 days ago - By: Traws Pharma, Inc.

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

21 days ago - By: ChemDiv

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

23 days ago - By: Benzinga - Mentions: AZTR SNTI ADAP CODX ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: Expert Systems, Inc.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

a month ago - By: Traws Pharma, Inc.

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

a month ago - By: Traws Pharma, Inc.

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

a month ago - By: Traws Pharma, Inc.

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

a month ago - By: Traws Pharma, Inc.

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

2 months ago - By: Annovis Bio Inc. - Mentions: ANVS

Annovis Appoints Mark Guerin as Chief Financial Officer

3 months ago - By: Traws Pharma, Inc.

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

3 months ago - By: Traws Pharma, Inc.

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

3 months ago - By: The Motley Fool - Mentions: ONTX

Traws Pharma Posts Q2 Revenue Jump

3 months ago - By: Traws Pharma, Inc.

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

3 months ago - By: Traws Pharma, Inc.

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

3 months ago - By: Traws Pharma, Inc.

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

3 months ago - By: Traws Pharma, Inc.

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

5 months ago - By: Stocktwits - Mentions: MRNA NVAX CVAC GSK

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

5 months ago - By: Traws Pharma, Inc.

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

5 months ago - By: Traws Pharma, Inc.

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

6 months ago - By: Traws Pharma, Inc.

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

6 months ago - By: Traws Pharma, Inc.

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

6 months ago - By: Traws Pharma, Inc.

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness